US specialty drugmaker Discovery Laboratories (Nasdaq: DSCO) saw its shares rocker 30% to $4.88 in after-hours trading yesterday, after the Food and Drug Administration approved its Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
Surfaxin is the first synthetic, peptide-containing surfactant approved for use in neonatal medicine, and Discovery Labs anticipates that the product will be commercially available in the USA in late 2012. Surfaxin, which was granted orphan drug status in 2006 but has previously been rejected by the FDA several times (The Pharma Letter April 21, 2009), becomes the fifth drug approved in the USA to treat RDS in premature infants. The other FDA-approved surfactants include Survanta (beractant), Curosurf (poractant alpha), Infasurf (calfactant), and Exosurf (colfosceril palmitate), which is no longer marketed, the agency noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze